Advertisement
Advertisement

Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

videocam
China technology

The next tech race? China launches push to leapfrog US in ‘brain chip’ devices

14
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

Chinese start-ups are developing brain-computer interfaces that can be implanted via a vein in just 10 minutes. Photo: Shutterstock
Chinese start-ups are developing brain-computer interfaces that can be implanted via a vein in just 10 minutes. Photo: Shutterstock
China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

Advertisement
Advertisement
Advertisement
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Washington is increasing scrutiny of Chinese biotech at a time when the innovation pipeline in the world’s second-largest economy is experiencing rapid growth. Photo: Shutterstock
Washington is increasing scrutiny of Chinese biotech at a time when the innovation pipeline in the world’s second-largest economy is experiencing rapid growth. Photo: Shutterstock
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

China’s private sector

‘Historic breakthrough’: China approves novel drug ahead of US, Japan and Europe

Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

Axiom Biosciences joins a swelling roster of healthcare firms seeking IPO approval in Hong Kong. Photo: Shutterstock
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

China’s private sector

Europe beckons: can Chinese medical device makers thrive amid trade barriers?

Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.

China’s private sector

Can AI collaborations power China’s next wave of blockbuster drug deals?

China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.

A pharmaceutical manufacturing line. Photo: Shutterstock
China’s private sector

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

videocam
Industry insiders say AI-powered drug-design tools have the potential to shorten development timelines from years to as few as 18 months. Photo: Shutterstock
Industry insiders say AI-powered drug-design tools have the potential to shorten development timelines from years to as few as 18 months. Photo: Shutterstock
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

China’s private sector

China’s first AI-powered cancer vaccine production line set to launch in Beijing

Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

HKEX pushes deeper into index business as AI reshapes Hong Kong market

The bourse wants proprietary indices to better capture China’s technology boom as traditional Hong Kong benchmarks trail regional peers.

Hong Kong Exchanges and Clearing at Exchange Square in Central. The bourse is expanding its index business with proprietary benchmarks and new investment products. Photo: Jelly Tse
Hong Kong Exchanges and Clearing at Exchange Square in Central. The bourse is expanding its index business with proprietary benchmarks and new investment products. Photo: Jelly Tse
China’s private sector

China is fretting over a demographic crisis – but what companies might benefit?

Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle.

China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock
China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

China’s private sector

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW